Download PDF
Open Access
CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2022; 05(02): 061-064
DOI: 10.1055/s-0042-1753496
Original Article

Comparison between Insulin Glargine and Insulin Detemir in Adolescents with Type 1 Diabetes during Ramadan Fasting

Authors

  • Walid Kaplan

    1   Department of Pediatric, Tawam Hospital, Al Ain, United Arab Emirates

  • Bachar Afandi 

    2   Department of Medicine, Tawam Hospital, Al Ain, United Arab Emirates

  • Noura Al Hassani 

    1   Department of Pediatric, Tawam Hospital, Al Ain, United Arab Emirates

Funding and Sponsorship None.
Further Information
Also available at
  Permissions and Reprints

Abstract

Objectives The aim of this study was to compare between insulin glargine and insulin detemir on glucose profile in adolescents with type 1 diabetes mellitus (T1DM) who fast the month of Ramadan.

Materials and Methods This was prospective, cross-over study. Subjects were randomized into Group G, in which insulin glargine was given once daily, and Group D, in which ⅔ of the total dose of insulin detemir was given before breaking the fast and ⅓ before starting it. Subjects were crossed-over after 1 week. We compared the mean interstitial glucose (IG), and the percentages of hypoglycemia (<70mg/dL) and severe hyperglycemia (>300mg/dL) between the groups.

Results A total of 11 adolescents were enrolled. Mean (±standard deviation) age was 14±3.3 years. There was no difference in the mean IG (190±46 vs. 198±37mg/dL, p=0.1), or the percentages of severe hyperglycemia (13.5±12.9% vs. 13.6±9.2%, p=0.5) in group G and Group D, respectively. Conversely, the percentage of hypoglycemia was higher in Group G than Group D (9.1±7.0% vs. 4.4±2.7%, respectively, p=0.01).

Conclusion Insulin detemir given twice daily results in less hypoglycemia than once daily insulin glargine in adolescents with T1DM during fasting in Ramadan.

Keywords

adolescents - detemir - glargine - Ramadan fasting

Author's Contribution

All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.


Compliance with Ethical Principles

The study complies with all relevant national regulations and institutional policies, and was reviewed and approved by our regional Institutional Review Board, reference number CRD IRR # 459/16.




Publication History

Article published online:
13 September 2022

© 2022. Gulf Association of Endocrinology and Diabetes (GAED). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India